Sulpivol

Quick links to important sections

Sulpivol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulpivol

Property Description
Active ingredient Sulpiride (Single entity)
Form Capsules, tablets, oral solution, solution for injection
Pharmacological class Antipsychotic Agent (Neuroleptic)
Common use Stabilization of severe mental state disruptions
Origin Synthetic (Substituted Benzamide derivative)

Sulpivol is a synthetic, prescription-only medication that contains the single active ingredient Sulpiride. It is classified as an Antipsychotic Agent (Neuroleptic) and is primarily used to help stabilize severe disruptions in mental state. Structurally, the drug's identity is defined as a substituted Benzamide derivative, placing it within a specific chemical class of pharmacological compounds.


Sulpivol's Pharmacological Class and Function

Sulpivol belongs to the pharmacological class of Antipsychotic Agents, medicines that influence the chemistry of the brain to regulate mood and perception. It functions primarily as a dopaminergic antagonist, meaning it helps to modulate the activity of the dopamine neurotransmitter system by selectively blocking the D2 and D3 receptors in specific areas of the central nervous system. This specific mechanism is clinically recognized for its differential effects at varying doses, contributing to its use for stabilizing thought processes and addressing certain mood-related disturbances. The core purpose of this action is to promote emotional stabilization and mental clarity.


Available Forms and Differentiation

The active ingredient, Sulpiride, is a synthetic molecule supplied in several distinct pharmaceutical preparations to allow for flexible administration. Sulpivol is available for oral use as capsules, tablets, and an oral solution. Its differentiation from generic formulations often rests on the consistency and specific profile of the oral forms. Additionally, it is manufactured as a solution for intramuscular injection, providing an alternative route of administration primarily used in clinical settings. The formulation uses standard inert pharmaceutical excipients to ensure the stability and consistent delivery of the Sulpiride molecule.

What side effects are possible with Sulpivol?

Possible Side Effects and Safety Information

The officially documented safety profile for Sulpivol (Sulpiride) is structured by regulatory bodies to classify potential adverse reactions based on frequency and affected physiological systems. This information is derived exclusively from government regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Common, include hyperprolactinemia, sedation, insomnia, dizziness, headache, and extrapyramidal disorder (such as tremor or parkinsonism). Less frequent, or Uncommon, effects include leukopenia, orthostatic hypotension, and QT interval prolongation (an ECG change). Agranulocytosis is classified as Rare.

Documented Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights several serious adverse reactions. These include the potential for Neuroleptic Malignant Syndrome (NMS), a severe complication, and the documented risk of Venous Thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Serious ventricular arrhythmias, such as Torsade de Pointes, are also noted safety concerns.

Specific limitations or restrictions apply to Sulpivol use. The medicine is contraindicated in individuals with certain pre-existing conditions, such as prolactin-dependent tumors and phaeochromocytoma.

Population and Exposure Safety Notes

Safety considerations for defined groups are also present. Older adults are noted to be more susceptible to certain effects, including postural hypotension and extrapyramidal symptoms, and the label carries a warning regarding the increased mortality risk for older patients with dementia-related psychosis. Dosage adjustments are specified for patients with renal impairment. Furthermore, some movement-related effects, such as acute dyskinesia, may occur early, while tardive dyskinesia is associated with long-term exposure, as is typical for antipsychotic agents.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Sulpivol (Sulpiride) is officially documented in regulatory sources as presenting with severe manifestations across two major physiological systems: the Central Nervous System (CNS) and the Cardiovascular System. Documented CNS effects include a progression of altered consciousness, ranging from over-sedation and confusion to potentially coma. Extrapyramidal disturbances are explicitly listed, such as acute dystonic crises (e.g., trismus, torticollis) and Parkinson's disease-like symptoms.

Severe Outcomes and Risks Required Emergency Action
The official profile highlights the potential for life-threatening cardiotoxicity, including signs like Q-T interval prolongation and the risk of developing serious ventricular arrhythmias, specifically torsade de pointes. The documented risk includes progression to cardiac arrest and sudden death. Immediate medical attention must be sought for any suspected overdose. Management is strictly limited to symptomatic and supportive treatment because no specific antidote is known.

Close medical monitoring is required to observe for cardiac rhythm disturbances and to manage symptomatic presentations. Extrapyramidal reactions may be managed using anticholinergic drugs as supportive measures documented in the official regulatory profile.

Therapeutic Uses of Sulpivol

Sulpivol (Sulpiride) is generally used to help with symptomatic relief in various clinical settings marked by heightened discomfort or tension. Its application is guided by the specific clusters of symptoms it helps ease, and supports the patient during difficult episodes by easing distress.

The medicine is relevant in contexts marked by increased discomfort or tension and is commonly used to help manage symptoms associated with schizophrenia, specific neurotic states, somatoform disorders, and severe behavioral disturbances like Tourette syndrome.

The use of the medicine is relevant when supportive symptom management is appropriate, as it assists with maintaining functional stability during episodes of heightened discomfort. It helps address symptom clusters that may become intense or disruptive, such as delusions and hallucinations, apathy and social withdrawal, pronounced dizziness or asthenia, and uncontrollable impulsiveness or tics.


Quick Summary: Relevant for managing Psychotic, Negative, and Somatic Symptom Axes

Eligibility and Restrictions for Use

The official regulatory profile for Sulpivol use is strictly defined by absolute prohibitions and mandatory restrictions.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults for established indications.

Populations for whom use is not recommended:

  • Children under 14 years (due to insufficient clinical experience).
  • Pregnant women and women of childbearing potential not using effective contraception.
  • Breastfeeding women.

Populations for whom use is contraindicated:

  • Patients with Hypersensitivity to sulpiride or its excipients.
  • Patients with Prolactin-dependent tumours (e.g., breast cancer) or Phaeochromocytoma.
  • Patients with Acute Porphyria.
  • Patients receiving concomitant treatment with Levodopa or related antiparkinsonian drugs.

Condition-specific eligibility rules:

  • Renal Impairment: Use is restricted; the dose must be reduced and carefully adjusted.
  • Cardiovascular Risk: Caution is required for patients with pre-existing heart disease, QT prolongation risk, or electrolyte imbalance.
  • Neurological Risk: Caution is required for patients with epilepsy (anti-convulsant therapy must be maintained) or Parkinson's Disease.
  • Older Adults: Caution is advised, particularly for those with dementia or cardiovascular risk factors; dose adjustment is mandatory if renal impairment is present.

Connection to the overall eligibility profile

Regulatory documents establish that use is contraindicated based on specific diseases or mandatory drug associations. Conditional use requires close monitoring for populations with organ impairment or pre-existing conditions like epilepsy or heart disease. This ensures the medicine is reserved for eligible adult populations where the risks can be appropriately managed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Description of Official Interaction
Formal Contraindication Reciprocal antagonism leading to a documented loss of effect for both agents, including dopaminergic antiparkinsonian medicines.
Cardiovascular Pharmacodynamic Risk Additive risk of QTc prolongation and serious ventricular arrhythmia (Torsade de pointes).
Absorption Interference Non-systemic agents decrease the oral exposure of Sulpiride by reducing its absorption.
CNS Depression Augmentation Additive effects resulting in enhanced central nervous system depression.

The official regulatory profile formally prohibits co-administration with Levodopa, classifying this as a contraindicated combination. Usage is not recommended with other medicinal products that prolong the QT interval due to the heightened, documented risk of ventricular arrhythmias. To prevent reduced drug exposure, administration rules require that Sulpiride must be taken at least two hours before agents such as Antacids or Sucralfate. Furthermore, consumption of Alcohol must be avoided as it enhances the sedative effects. The official profile notes that Sulpiride is documented as having no clinically significant interactions mediated through the major human Cytochrome P450 enzyme pathways. Elderly patients are noted as being more susceptible to enhanced postural hypotension and sedation resulting from documented pharmacodynamic interactions. The interaction structure is defined primarily by pharmacodynamic avoidance rules and pharmacokinetic timing constraints.

Mechanism of Action

Sulpivol acts primarily as a selective antagonist at central dopamine D2 receptors (D2R), a member of the G protein-coupled receptor (GPCR) family. The drug molecule binds to the D2R with high affinity, competitively blocking the binding of the endogenous neurotransmitter dopamine.

In the mesolimbic and nigrostriatal dopaminergic pathways, this antagonism disrupts the post-synaptic transmission of dopaminergic signals. At lower systemic concentrations, Sulpivol preferentially blocks presynaptic D2-autoreceptors. This blockade reduces the autoreceptor-mediated negative feedback mechanism, leading to a subsequent increase in the release of dopamine into the synaptic cleft. The overall systemic effect is a modulation of both pre- and post-synaptic dopaminergic activity, leading to system-level physiological changes in central motor function and neuroendocrine regulation, particularly in the hypothalamic-pituitary-adrenal (HPA) axis, and enhanced gastrointestinal motility via D2 antagonism in the gut, which disinhibits acetylcholine release.

Dosage and Administration Information

How to Use Sulpivol

Sulpivol (Sulpiride) is administered according to specific, documented usage patterns.


Administration Scope and Dosing

Feature Official Usage Guideline
Route of Administration The primary route for maintenance treatment is oral, available as tablets, capsules, and solution. The medicine is also supplied as a solution for intramuscular injection for use in acute settings.
Dosing Schedule The official dose range is highly varied, typically administered in divided doses twice daily (morning and evening). The specific dose, which may range from 200 mg up to 2400 mg daily, is determined by the specific clinical requirements.
Administration Context Tablets must be swallowed whole with water and are not to be crushed or chewed. The medication can be taken with or without food.

Procedural and Population Requirements

Feature Official Usage Guideline
Renal Adjustment For patients with impaired kidney function, the dose must be reduced or the time interval between doses must be extended to account for reduced elimination.
Special Supervision Initiation of treatment for specific conditions should be carried out under the supervision of a specialist.
Duration and Cessation Treatment often involves an initial stabilization phase followed by a long-term maintenance phase. Discontinuation of Sulpivol requires a slow and gradual reduction in dosage.
Pediatric Use The use of Sulpivol is not recommended in children under 14 years.

The official protocol for Sulpivol use is structured by the requirement to correctly select a dose from a wide established range, administer it in divided daily doses, and adhere to mandatory procedural rules for administration and discontinuation, ensuring specific modifications are made if the user has documented renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored the tolerability of this new drug in the context of chronic neuropathic pain. Clinical studies examined changes in pain levels in participants who had not responded to first-line therapies.

This information is not a substitute for professional medical advice.


Overview of Key Studies: Research Findings

Study 1: Evaluation of Pain Score Changes

This randomized, controlled trial (RCT) evaluated whether there was an association with changes in patient outcomes over a 12-week period.

The primary endpoint measured was the change in pain scores. In the active group, the average VAS pain score shifted from 7.2 to 3.1, in contrast to a smaller shift observed in the placebo group. The overall patient-reported quality of life measures were also analyzed.

These findings were part of the data used to assess the drug's profile.


Study 2: Long-term Tolerability Evaluation

A 6-month extension study evaluated the drug's safety profile and examined pain scores with continued use. The study focused on the potential for sustained changes in pain and tolerability over the extended period.

The study reported no new safety signals during the 6-month extension. The study findings described the side effect profile, noting that most events reported were non-severe, as part of the overall tolerability assessment.


Note on Specific Populations

The study did not specifically look at people with liver impairment. Further research may be required to fully characterize the drug's metabolism in this population.

Frequently Asked Questions (FAQ)

Common questions about Sulpivol (FAQ)


Q: What is the main reason a doctor might prescribe Sulpivol?

A: Sulpivol is primarily prescribed to help manage and prevent the return of symptoms associated with Schizophrenia and other severe mental state disruptions. Official documents also indicate that at lower doses, it is sometimes used to address symptoms of depression or anxiety for short-term periods, depending on the professional assessment.

Q: How does Sulpivol differ from other medicines that treat the same thing?

A: Sulpivol is described in official pharmacological information as a first-generation antipsychotic agent. It works as a highly selective antagonist, meaning it primarily blocks certain dopamine D2 receptors in the brain. Its specific pharmacological profile and unique structure as a substituted Benzamide derivative help differentiate it from other medications in its class.

Q: Why is Sulpivol given in different dosages for the same condition?

A: Regulatory documents describe a wide range of possible doses for Sulpivol. The official dose is highly individualized and is adjusted based on a person’s specific clinical condition, age, and existing kidney function. This wide, labelled range allows for the prescribed dose to be determined according to the individual's condition.

Q: Can Sulpivol be taken long-term?

A: Treatment protocols often describe an initial phase followed by a long-term maintenance phase. Long-term use is associated with the potential for documented effects, such as tardive dyskinesia. This is a movement-related effect seen with prolonged exposure to this type of medication.

Q: Is Sulpivol known to interact with common over-the-counter supplements?

A: Official guidance indicates that information about all substances being taken, including over-the-counter supplements, traditional medicine, and herbal products, is important for the prescribing health professional. This is because some of these substances may affect how Sulpivol works in the body.

Q: Can Sulpivol be used by people with kidney problems?

A: Regulatory labels confirm that Sulpivol can be used by people with kidney problems, but with necessary adjustments. Regulatory documents describe that the regimen for Sulpivol may require adjustment to account for reduced elimination when a patient has impaired kidney function.

Q: What is the main evidence that Sulpivol is effective?

A: Clinical trials and studies, which form the basis of regulatory approval, have primarily focused on its use in the management of severe conditions, particularly schizophrenia and chronic depression. It has also been explored as an augmentation therapy to support the action of other medications.

Q: Will Sulpivol show up on a standard drug test?

A: Sulpivol is a compound for which specialized laboratory assays are established. These tests are used by health professionals for purposes such as Therapeutic Drug Monitoring (TDM) to measure the concentration of the compound in a person's system.

Q: Is there a generic version of Sulpivol available?

A: Yes. The active ingredient in Sulpivol is Sulpiride. Official documents often reference the drug by both the brand name and the generic name, indicating that generic forms of Sulpiride are available.

Q: How long does Sulpivol stay in your system?

A: Official clinical pharmacology data indicates that the plasma half-life of Sulpiride is typically between 6 and 8 hours. The half-life is the amount of time it takes for the concentration of the medicine in the blood to be reduced by half.

Q: Can Sulpivol affect my ability to drive or operate machinery?

A: Yes. Official labels carry a warning that this medicine may cause effects such as sleepiness, dizziness, or light-headedness. Regulatory documents describe that caution regarding the ability to drive a car or operate dangerous machinery is necessary when taking Sulpivol.

Q: Is Sulpivol generally considered suitable for people who have liver disease?

A: Regulatory documents note that caution and professional consultation are required for patients who have or have ever had liver disease. Official labeling also notes that further research is sometimes required to fully understand the drug’s metabolism in this population.

Q: Are there any documented long-term side effects that official sources describe?

A: Yes, regulatory documentation describes several documented long-term effects. The movement-related disorder tardive dyskinesia is described in official labeling as associated with long-term exposure. Other potential long-term risks include those related to sustained high levels of the hormone prolactin.

Q: Can Sulpivol cause changes in mood or sleeping patterns?

A: Official side effect classifications list insomnia (difficulty sleeping) as a Common side effect of Sulpivol. Additionally, the drug itself works by modulating brain chemistry to address mood-related disturbances.

Q: What is the risk of stopping Sulpivol suddenly?

A: Official regulatory documents emphasize that discontinuation of this treatment requires a slow and gradual reduction in dosage. This gradual reduction procedure is necessary to help minimize the potential for undesirable effects that can occur with abrupt cessation.

Q: Why is Sulpivol sometimes prescribed alongside other medications?

A: Research indicates that Sulpivol is sometimes used as an add-on drug (or augmentation therapy). This strategy is employed to support the action of another antipsychotic, particularly for individuals whose condition has shown resistance to single-drug treatments.

Q: Are there specific times of day that Sulpivol is intended to be taken?

A: Yes. The official dosing schedule for Sulpivol is typically administered in divided doses twice daily, with the morning and evening specified as the intended times. This helps maintain a stable level of the medicine in the body.

Q: Are there specific warnings for Sulpivol related to sun exposure?

A: Official labeling includes a specific warning that the medication can make your skin more sensitive to sunlight (photosensitivity). Patients may need to consider protective measures, such as using sunscreen or wearing protective clothing, to avoid prolonged sun exposure.

Q: Is Sulpivol a daily medication, or is it taken as needed?

A: Sulpivol is intended to be a daily medication. It is typically administered in divided doses twice daily and often involves a long-term maintenance phase to help stabilize the patient’s condition over time.

Q: What kind of studies were used to approve Sulpivol for use?

A: The data used for regulatory approval is based on various types of clinical trials. These studies include Randomized Controlled Trials (RCTs) and long-term extension studies, which are designed to thoroughly evaluate both the efficacy (how well it works) and the safety profile of the drug.

Q: Does the efficacy of Sulpivol change over time with continued use?

A: Long-term studies have been conducted to evaluate both the safety profile and the efficacy of Sulpivol with continued use. Long-term studies have explored continued efficacy, but the results described are sometimes mixed and relate to the specific medical condition examined.

Q: Are people with a history of seizures eligible to use Sulpivol?

A: Official documents note that caution is required for people with epilepsy (a condition characterized by seizures). Regulatory documents note that if a patient has epilepsy, anti-convulsant therapy is generally managed alongside Sulpivol. Caution is required in this patient population.

Q: What happens if I miss a dose of Sulpivol?

A: Official regulatory documents provide specific procedures for handling a missed dose. These instructions outline how to proceed based on the time elapsed and the proximity to the next scheduled dose.

Q: Do I need to take Sulpivol with food?

A: The official usage guideline for Sulpivol states that the medication can be taken with or without food. Taking it with food is not a mandatory requirement for its absorption or effectiveness.

Q: Can I crush or split my Sulpivol tablet?

A: No. Official administration instructions state that the tablets must be swallowed whole with water. They are explicitly not to be crushed or chewed to ensure the medication works as intended in the body.

Q: What happens if I accidentally take more Sulpivol than prescribed?

A: Official patient information describes that in the event a person accidentally takes more than the prescribed dose, professional consultation is required. This is a safety measure to manage any potential adverse effects.

Q: How quickly do the effects of Sulpivol typically wear off?

A: The amount of drug in the body is typically reduced by half (known as the plasma half-life) in 6 to 8 hours. This pharmacokinetic information helps determine the twice-daily dosing schedule to maintain therapeutic levels.

How should Sulpivol be stored and disposed of?

How to Store and Dispose of Sulpivol?

Sulpivol (Sulpiride) must be stored under specific environmental controls as defined in regulatory labeling. Oral solid forms are required to be stored at a temperature not exceeding 25 C and must be kept in the original container.

Required Storage and Protection

Storage Condition Requirement
Temperature Store at or below 25 C (77 F).
Protection Must be protected from light and moisture.
Child Safety Keep out of the sight and reach of children.

The medicine must not be frozen to maintain product integrity. Regarding disposal, unused or expired Sulpivol should be taken to an official drug take-back program. If this is not possible, regulatory guidance permits mixing the medicine with an undesirable substance and discarding it in the household trash. The product must not be flushed down the toilet or poured into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulpivol found in:

A-Z Index: